This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., Honjo T.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol., 1996; 8: 765–772AgataY.KawasakiA.NishimuraH.IshidaY.TsubataT.YagitaH.HonjoT.Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInt. Immunol.1996876577210.1093/intimm/8.5.7658671665Search in Google Scholar
Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M., Kageyama K., Imagawa A., Akamizu T.: Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019; 66: 581–586ArimaH.IwamaS.InabaH.AriyasuH.MakitaN.OtsukiM.KageyamaK.ImagawaA.AkamizuT.Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine SocietyEndocr. J.20196658158610.1507/endocrj.EJ19-016331243183Search in Google Scholar
Armand P., Chen Y.B., Redd R.A., Joyce R.M., Bsat J., Jeter E., Merryman R.W., Coleman K.C., Dahi P.B., Nieto Y., LaCasce A.S., Fisher D.C., Ng S.Y., Odejide O.O., Freedman A.S., et al.: PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019; 134: 22–29ArmandP.ChenY.B.ReddR.A.JoyceR.M.BsatJ.JeterE.MerrymanR.W.ColemanK.C.DahiP.B.NietoY.LaCasceA.S.FisherD.C.NgS.Y.OdejideO.O.FreedmanA.S.PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationBlood2019134222910.1182/blood.2019000215660995530952672Search in Google Scholar
Bavencio – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/bavencio-epar-product-information_en.pdf (25.09.2020)Bavencio – Summary of Product Characteristicshttps://www.ema.europa.eu/en//documents/product-information/bavencio-epar-product-information_en.pdf (25.09.2020)Search in Google Scholar
Bhasin S., Brito J.P., Cunningham G.R., Hayes F.J., Hodis H.N., Matsumoto A.M., Snyder P.J., Swerdloff R.S., Wu F.C., Yialamas M.A.: Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2018; 103: 1715–1744BhasinS.BritoJ.P.CunninghamG.R.HayesF.J.HodisH.N.MatsumotoA.M.SnyderP.J.SwerdloffR.S.WuF.C.YialamasM.A.Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice GuidelineJ. Clin. Endocrinol. Metab.20181031715174410.1210/jc.2018-0022929562364Search in Google Scholar
Bornstein S.R., Allolio B., Arlt W., Barthel A., Don-Wauchope A., Hammer G.D., Husebye E.S., Merke D.P., Murad M.H., Stratakis C.A., Torpy D.J.: Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2016; 101: 364–389BornsteinS.R.AllolioB.ArltW.BarthelA.Don-WauchopeA.HammerG.D.HusebyeE.S.MerkeD.P.MuradM.H.StratakisC.A.TorpyD.J.Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice GuidelineJ. Clin. Endocrinol. Metab.201610136438910.1210/jc.2015-1710488011626760044Search in Google Scholar
Carlé A., Pedersen I.B., Knudsen N., Perrild H., Ovesen L., Andersen S., Laurberg P.: Hypothyroid symptoms fail to predict thyroid insufficiency in old people: A population-based case-control study. Am. J. Med., 2016; 129: 1082–1092CarléA.PedersenI.B.KnudsenN.PerrildH.OvesenL.AndersenS.LaurbergP.Hypothyroid symptoms fail to predict thyroid insufficiency in old people: A population-based case-control studyAm. J. Med.20161291082109210.1016/j.amjmed.2016.06.01327393881Search in Google Scholar
Caturegli P., Di Dalmazi G., Lombardi M., Grosso F., Larman H.B., Larman T., Taverna G., Cosottini M., Lupi I.: Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series. Am. J. Pathol., 2016; 186: 3225–3235CaturegliP.Di DalmaziG.LombardiM.GrossoF.LarmanH.B.LarmanT.TavernaG.CosottiniM.LupiI.Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy seriesAm. J. Pathol.20161863225323510.1016/j.ajpath.2016.08.020522529427750046Search in Google Scholar
Caturegli P., Newschaffer C., Olivi A., Pomper M.G., Burger P.C., Rose N.R.: Autoimmune hypophysitis. Endocr. Rev., 2005; 26: 599–614CaturegliP.NewschafferC.OliviA.PomperM.G.BurgerP.C.RoseN.R.Autoimmune hypophysitisEndocr. Rev.20052659961410.1016/B978-0-12-384929-8.00045-9Search in Google Scholar
Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., Fong L.: Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med., 2014; 6: 238ra70ChaE.KlingerM.HouY.CummingsC.RibasA.FahamM.FongL.Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patientsSci. Transl. Med.20146238ra7010.1126/scitranslmed.3008211455809924871131Search in Google Scholar
Chabner B.A., Roberts T.G. Jr.: Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005; 5: 65–72ChabnerB.A.RobertsT.G.Jr.Timeline: Chemotherapy and the war on cancerNat. Rev. Cancer20055657210.1038/nrc152915630416Search in Google Scholar
Chalan P., Di Dalmazi G., Pani F., De Remigis A., Caturegli P.: Thyroid dysfunctions secondary to cancer immunotherapy. J. Endocrinol. Invest., 2018; 41: 625–638ChalanP.Di DalmaziG.PaniF.De RemigisA.CaturegliP.Thyroid dysfunctions secondary to cancer immunotherapyJ. Endocrinol. Invest.20184162563810.1007/s40618-017-0778-8Search in Google Scholar
Chamberlain J.J., Rhinehart A.S., Shaefer C.F. Jr, Neuman A.: Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann. Intern. Med., 2016; 164: 542–552ChamberlainJ.J.RhinehartA.S.ShaeferC.F.JrNeumanA.Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association standards of medical care in diabetesAnn. Intern. Med.201616454255210.7326/M15-3016Search in Google Scholar
Chang L.S., Barroso-Sousa R., Tolaney S.M., Hodi F.S, Kaiser U.B., Min L.: Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev., 2019; 40: 17–65ChangL.S.Barroso-SousaR.TolaneyS.M.HodiF.SKaiserU.B.MinL.Endocrine toxicity of cancer immunotherapy targeting immune checkpointsEndocr. Rev.201940176510.1210/er.2018-00006Search in Google Scholar
Chau C.H., Steeg P.S, Figg W.D.: Antibody-drug conjugates for cancer. Lancet, 2019; 394: 793–804ChauC.H.SteegP.SFiggW.D.Antibody-drug conjugates for cancerLancet201939479380410.1016/S0140-6736(19)31774-XSearch in Google Scholar
Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F.: Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375CorselloS.M.BarnabeiA.MarchettiP.De VecchisL.SalvatoriR.TorinoF.Endocrine side effects induced by immune checkpoint inhibitorsJ. Clin. Endocrinol. Metab.2013981361137510.1210/jc.2012-407523471977Search in Google Scholar
Darvin P., Toor S.M., Nair V.S., Elkord E.: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med., 2018; 50: 1–11DarvinP.ToorS.M.NairV.S.ElkordE.Immune checkpoint inhibitors: Recent progress and potential biomarkersExp. Mol. Med.20185011110.1038/s12276-018-0191-1629289030546008Search in Google Scholar
De Filette J., Andreescu C.E., Cools F., Bravenboer B., Velkeniers B.: A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res., 2019; 51: 145–156De FiletteJ.AndreescuC.E.CoolsF.BravenboerB.VelkeniersB.A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitorsHorm. Metab. Res.20195114515610.1055/a-0843-336630861560Search in Google Scholar
Dillard T., Yedinak C.G., Alumkal J., Fleseriu M.: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary, 2010; 13: 29–38DillardT.YedinakC.G.AlumkalJ.FleseriuM.Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypesPituitary201013293810.1007/s11102-009-0193-z19639414Search in Google Scholar
Dyrka K., Miedziaszczyk M., Szałek E., Łącka K.: Drugs used in viral diseases – their mechanism of action, selected adverse effects and safety during pregnancy and lactation. Postępy Hig. Med. Dośw., 2019; 73: 491–507DyrkaK.MiedziaszczykM.SzałekE.ŁąckaK.Drugs used in viral diseases – their mechanism of action, selected adverse effects and safety during pregnancy and lactationPostępy Hig. Med. Dośw.20197349150710.5604/01.3001.0013.5249Search in Google Scholar
Emens L.A., Cruz C., Eder J.P., Braiteh F., Chung C., Tolaney S.M., Kuter I., Nanda R., Cassier P.A., Delord J.P., Gordon M.S., ElGabry E., Chang C.W., Sarkar I., Grossman W., et al.: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol., 2019; 5: 74–82EmensL.A.CruzC.EderJ.P.BraitehF.ChungC.TolaneyS.M.KuterI.NandaR.CassierP.A.DelordJ.P.GordonM.S.ElGabryE.ChangC.W.SarkarI.GrossmanW.Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 studyJAMA Oncol.20195748210.1001/jamaoncol.2018.4224643977330242306Search in Google Scholar
Faje A.T., Sullivan R., Lawrence D., Tritos N.A., Fadden R., Klibanski A., Nachtigall L.: Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab., 2014; 99: 4078–4085FajeA.T.SullivanR.LawrenceD.TritosN.A.FaddenR.KlibanskiA.NachtigallL.Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanomaJ. Clin. Endocrinol. Metab.2014994078408510.1210/jc.2014-230625078147Search in Google Scholar
Fassett D.R., Couldwell W.T.: Metastases to the pituitary gland. Neurosurg. Focus., 2004; 16: E8FassettD.R.CouldwellW.T.Metastases to the pituitary glandNeurosurg. Focus.200416E810.3171/foc.2004.16.4.9Search in Google Scholar
Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F.: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer, 2018; 103: 356–387FerlayJ.ColombetM.SoerjomataramI.DybaT.RandiG.BettioM.GavinA.VisserO.BrayF.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018Eur. J. Cancer201810335638710.1016/j.ejca.2018.07.00530100160Search in Google Scholar
Ferrari S.M., Fallahi P., Galetta F., Citi E., Benvenga S., Antonelli A.: Thyroid disorders induced by checkpoint inhibitors. Rev. Endocr. Metab. Disord., 2018; 19: 325–333FerrariS.M.FallahiP.GalettaF.CitiE.BenvengaS.AntonelliA.Thyroid disorders induced by checkpoint inhibitorsRev. Endocr. Metab. Disord.20181932533310.1007/s11154-018-9463-230242549Search in Google Scholar
Freeman-Keller M., Kim Y., Cronin H., Richards A., Gibney G., Weber J.S.: Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res., 2016; 22: 886–894Freeman-KellerM.KimY.CroninH.RichardsA.GibneyG.WeberJ.S.Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomesClin. Cancer Res.20162288689410.1158/1078-0432.CCR-15-1136475580926446948Search in Google Scholar
Gauci M.L., Laly P., Vidal-Trecan T., Baroudjian B., Gottlieb J., Madjlessi-Ezra N., Da Meda L., Madelaine-Chambrin I., Bagot M., Basset-Seguin N., Pages C., Mourah S., Boudou P., Lebbé C., Gautier J.F.: Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review. Cancer Immunol. Immunother., 2017; 66: 1399–1410GauciM.L.LalyP.Vidal-TrecanT.BaroudjianB.GottliebJ.Madjlessi-EzraN.Da MedaL.Madelaine-ChambrinI.BagotM.Basset-SeguinN.PagesC.MourahS.BoudouP.LebbéC.GautierJ.F.Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature reviewCancer Immunol. Immunother.2017661399141010.1007/s00262-017-2033-828634815Search in Google Scholar
Gharwan H., Groninger H.: Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications. Nat. Rev. Clin. Oncol., 2016; 13: 209–227GharwanH.GroningerH.Kinase inhibitors and monoclonal antibodies in oncology: Clinical implicationsNat. Rev. Clin. Oncol.20161320922710.1038/nrclinonc.2015.21326718105Search in Google Scholar
Ha D., Tanaka A., Kibayashi T., Tanemura A., Sugiyama D., Wing J.B., Lim E.L., Teng K.W., Adeegbe D., Newell E.W., Katayama I., Nishikawa H., Sakaguchi S.: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc. Natl. Acad. Sci. USA, 2019; 116: 609–618HaD.TanakaA.KibayashiT.TanemuraA.SugiyamaD.WingJ.B.LimE.L.TengK.W.AdeegbeD.NewellE.W.KatayamaI.NishikawaH.SakaguchiS.Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibodyProc. Natl. Acad. Sci. USA201911660961810.1073/pnas.1812186116632997930587582Search in Google Scholar
Haanen J.B., Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K., ESMO Guidelines Committee: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2017; 28: iv119–iv142HaanenJ.B.CarbonnelF.RobertC.KerrK.M.PetersS.LarkinJ.JordanK.ESMO Guidelines CommitteeManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn. Oncol.201728iv119iv14210.1093/annonc/mdx22528881921Search in Google Scholar
Haanen J.B., Robert C.: Immune checkpoint inhibitors. Prog. Tumor Res., 2015; 42: 55–66HaanenJ.B.RobertC.Immune checkpoint inhibitorsProg. Tumor Res.201542556610.1159/00043717826382943Search in Google Scholar
Hafeez U., Gan H.K., Scott A.M.: Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr. Opin. Pharmacol., 2018; 41: 114–121HafeezU.GanH.K.ScottA.M.Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseasesCurr. Opin. Pharmacol.20184111412110.1016/j.coph.2018.05.010Search in Google Scholar
Hodi F.S., Chesney J., Pavlick A.C., Robert C., Grossman K.F., McDermott D.F., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., Ernstoff M.S., Minor D.R., Salama A.K., Taylor M.H., et al.: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol., 2016; 17: 1558–1568HodiF.S.ChesneyJ.PavlickA.C.RobertC.GrossmanK.F.McDermottD.F.LinetteG.P.MeyerN.GiguereJ.K.AgarwalaS.S.ShaheenM.ErnstoffM.S.MinorD.R.SalamaA.K.TaylorM.H.Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialLancet Oncol.2016171558156810.1016/S1470-2045(16)30366-7Search in Google Scholar
Horn L., Mansfield A.S., Szczęsna A., Havel L., Krzakowski M., Hochmair M.J., Huemer F., Losonczy G., Johnson M.L., Nishio M., Reck M., Mok T., Lam S., Shames D.S., Liu J., et al.: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med., 2018; 379: 2220–2229HornL.MansfieldA.S.SzczęsnaA.HavelL.KrzakowskiM.HochmairM.J.HuemerF.LosonczyG.JohnsonM.L.NishioM.ReckM.MokT.LamS.ShamesD.S.LiuJ.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancerN. Engl. J. Med.20183792220222910.1056/NEJMoa180906430280641Search in Google Scholar
Iglesias P.: Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. Eur. J. Intern. Med., 2018; 47: 6–13IglesiasP.Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approachEur. J. Intern. Med.20184761310.1016/j.ejim.2017.08.01928826822Search in Google Scholar
Illouz F., Briet C., Cloix L., Le Corre Y., Baize N., Urban T., Martin L., Rodien P.: Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists. Cancer Med., 2017; 6: 1923–1929IllouzF.BrietC.CloixL.Le CorreY.BaizeN.UrbanT.MartinL.RodienP.Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologistsCancer Med.201761923192910.1002/cam4.1145554887628719055Search in Google Scholar
Imfinzi – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/imfizi-epar-product-information_en.pdf (25.09.2020)Imfinzi – Summary of Product Characteristicshttps://www.ema.europa.eu/en//documents/product-information/imfizi-epar-product-information_en.pdf (25.09.2020)Search in Google Scholar
Iwama S., De Remigis A., Callahan M.K., Slovin S.F., Wolchok J.D., Caturegli P.: Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med., 2014; 6: 230ra45IwamaS.De RemigisA.CallahanM.K.SlovinS.F.WolchokJ.D.CaturegliP.Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibodySci. Transl. Med.20146230ra4510.1126/scitranslmed.300800224695685Search in Google Scholar
Iyer P.C., Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S.N., Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid, 2018; 28: 1243–1251IyerP.C.CabanillasM.E.WaguespackS.G.HuM.I.ThosaniS.N.LavisV.R.BusaidyN.L.SubudhiS.K.DiabA.DaduR.Immune-related thyroiditis with immune checkpoint inhibitorsThyroid2018281243125110.1089/thy.2018.0116615735930132401Search in Google Scholar
Joo W.D., Visintin I., Mor G.: Targeted cancer therapy – Are the days of systemic chemotherapy numbered? Maturitas, 2013; 76: 308–314JooW.D.VisintinI.MorG.Targeted cancer therapy – Are the days of systemic chemotherapy numbered?Maturitas20137630831410.1016/j.maturitas.2013.09.008461002624128673Search in Google Scholar
Joshi M.N., Whitelaw B.C., Palomar M.T., Wu Y., Carroll P.V.: Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin. Endocrinol., 2016; 85: 331–339JoshiM.N.WhitelawB.C.PalomarM.T.WuY.CarrollP.V.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical reviewClin. Endocrinol.20168533133910.1111/cen.1306326998595Search in Google Scholar
June C.H., Warshauer J.T., Bluestone J.A.: Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat. Med., 2017; 23: 540–547JuneC.H.WarshauerJ.T.BluestoneJ.A.Is autoimmunity the Achilles’ heel of cancer immunotherapy?Nat. Med.20172354054710.1038/nm.432128475571Search in Google Scholar
Kalogeras K.T., Nieman L.K., Friedman T.C., Doppman J.L., Cutler G.B. Jr, Chrousos G.P., Wilder R.L., Gold P.W., Yanovski J.A.: Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. J Clin Invest., 1996; 97: 2045–2050KalogerasK.T.NiemanL.K.FriedmanT.C.DoppmanJ.L.CutlerG.B.JrChrousosG.P.WilderR.L.GoldP.W.YanovskiJ.A.Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretionJ Clin Invest.1996972045205010.1172/JCI1186405072788621793Search in Google Scholar
Katzke V.A., Kaaks R., Kühn T.: Lifestyle and cancer risk. Cancer J., 2015; 21: 104–110KatzkeV.A.KaaksR.KühnT.Lifestyle and cancer riskCancer J.20152110411010.1097/PPO.000000000000010125815850Search in Google Scholar
Keytruda – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (25.09.2020)Keytruda – Summary of Product Characteristicshttps://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (25.09.2020)Search in Google Scholar
Konda B., Nabhan F., Shah M.H.: Endocrine dysfunction following immune checkpoint inhibitor therapy. Curr. Opin. Endocrinol. Diabetes Obes., 2017; 24: 337–347KondaB.NabhanF.ShahM.H.Endocrine dysfunction following immune checkpoint inhibitor therapyCurr. Opin. Endocrinol. Diabetes Obes.20172433734710.1097/MED.000000000000035728661915Search in Google Scholar
Lam K.Y., Lo C.Y.: Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospital. Clin. Endocrinol., 2002; 56: 95–101LamK.Y.LoC.Y.Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospitalClin. Endocrinol.2002569510110.1046/j.0300-0664.2001.01435.x11849252Search in Google Scholar
Lee Y.T., Tan Y.J, Oon C.E.: Molecular targeted therapy: Treating cancer with specificity. Eur. J. Pharmacol., 2018; 834: 188–196LeeY.T.TanY.JOonC.E.Molecular targeted therapy: Treating cancer with specificityEur. J. Pharmacol.201883418819610.1016/j.ejphar.2018.07.03430031797Search in Google Scholar
Liu M., Guo F.: Recent updates on cancer immunotherapy. Precis Clin. Med., 2018; 1: 65–74LiuM.GuoF.Recent updates on cancer immunotherapyPrecis Clin. Med.20181657410.1093/pcmedi/pby011633304530687562Search in Google Scholar
Lupi I., Zhang J., Gutenberg A., Landek-Salgado M., Tzou S.C., Mori S., Caturegli P.: From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis. Endocrinology, 2011; 152: 4190–4198LupiI.ZhangJ.GutenbergA.Landek-SalgadoM.TzouS.C.MoriS.CaturegliP.From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitisEndocrinology20111524190419810.1210/en.2011-1004319899421862619Search in Google Scholar
Manohar S., Kompotiatis P., Thongprayoon C., Cheungpasitporn W., Herrmann J., Herrmann S.M.: Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol. Dial. Transplant., 2019; 34: 108–117ManoharS.KompotiatisP.ThongprayoonC.CheungpasitpornW.HerrmannJ.HerrmannS.M.Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysisNephrol. Dial. Transplant.20193410811710.1093/ndt/gfy10529762725Search in Google Scholar
Marin-Acevedo J.A., Soyano A.E., Dholaria B., Knutson K.L., Lou Y.: Cancer immunotherapy beyond immune checkpoint inhibitors. J. Hematol. Oncol., 2018; 11: 8Marin-AcevedoJ.A.SoyanoA.E.DholariaB.KnutsonK.L.LouY.Cancer immunotherapy beyond immune checkpoint inhibitorsJ. Hematol. Oncol.201811810.1186/s13045-017-0552-6576705129329556Search in Google Scholar
Min L., Hodi F.S., Giobbie-Hurder A., Ott P.A., Luke J.J., Donahue H., Davis M., Carroll R.S., Kaiser U.B.: Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin. Cancer Res., 2015; 21: 749–755MinL.HodiF.S.Giobbie-HurderA.OttP.A.LukeJ.J.DonahueH.DavisM.CarrollR.S.KaiserU.B.Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort studyClin. Cancer Res.20152174975510.1158/1078-0432.CCR-14-2353433469725538262Search in Google Scholar
Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Vance M.L., Endocrine Society: Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011; 96: 1587–1609MolitchM.E.ClemmonsD.R.MalozowskiS.MerriamG.R.VanceM.L.Endocrine SocietyEvaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guidelineJ. Clin. Endocrinol. Metab.2011961587160910.1210/jc.2011-017921602453Search in Google Scholar
Ni J., Qiu L.J., Zhang M., Wen P.F., Ye X.R., Liang Y., Pan H.F., Ye D.Q.: CTLA-4 CT60 (rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: A comprehensive meta-analysis. Endocr. Res., 2014; 39: 180–188NiJ.QiuL.J.ZhangM.WenP.F.YeX.R.LiangY.PanH.F.YeD.Q.CTLA-4 CT60 (rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: A comprehensive meta-analysisEndocr. Res.20143918018810.3109/07435800.2013.87916724697361Search in Google Scholar
Oelkers W.: Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N. Engl. J. Med., 1989; 321: 492–496OelkersW.Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarismN. Engl. J. Med.198932149249610.1056/NEJM1989082432108022548097Search in Google Scholar
Opdivo – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (25.09.2020)Opdivo – Summary of Product Characteristicshttps://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (25.09.2020)Search in Google Scholar
Parakh S., King D., Gan H.K., Scott A.M.: Current development of monoclonal antibodies in cancer therapy. Recent Res. Cancer Res., 2020; 214: 1–70ParakhS.KingD.GanH.K.ScottA.M.Current development of monoclonal antibodies in cancer therapyRecent Res. Cancer Res.202021417010.1007/978-3-030-23765-3_131473848Search in Google Scholar
Pardoll D.M.: The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 2012; 12: 252–264PardollD.M.The blockade of immune checkpoints in cancer immunotherapyNat. Rev. Cancer20121225226410.1038/nrc3239485602322437870Search in Google Scholar
Persani L., Ferretti E., Borgato S., Faglia G., Beck-Peccoz P.: Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J. Clin. Endocrinol. Metab., 2000; 85: 3631–3635PersaniL.FerrettiE.BorgatoS.FagliaG.Beck-PeccozP.Circulating thyrotropin bioactivity in sporadic central hypothyroidismJ. Clin. Endocrinol. Metab.2000853631363510.1210/jc.85.10.3631Search in Google Scholar
Peters C., Brown S.: Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep., 2015; 35: e00225PetersC.BrownS.Antibody-drug conjugates as novel anti-cancer chemotherapeuticsBiosci. Rep.201535e0022510.1042/BSR20150089461371226182432Search in Google Scholar
Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab., 2019; 104: 550–556PiranavanP.LiY.BrownE.KempE.H.TrivediN.Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodiesJ. Clin. Endocrinol. Metab.201910455055610.1210/jc.2018-0115130252069Search in Google Scholar
Puar T.H., Stikkelbroeck N.M., Smans L.C., Zelissen P.M., Hermus A.R.: Adrenal crisis: Still a deadly event in the 21st century. Am. J. Med., 2016; 129: 339.e1–9PuarT.H.StikkelbroeckN.M.SmansL.C.ZelissenP.M.HermusA.R.Adrenal crisis: Still a deadly event in the 21st centuryAm. J. Med.2016129339.e1910.1016/j.amjmed.2015.08.02126363354Search in Google Scholar
Raghavan R., Brady M.L., Sampson J.H.: Delivering therapy to target: Improving the odds for successful drug development. Ther. Deliv., 2016; 7: 457–481RaghavanR.BradyM.L.SampsonJ.H.Delivering therapy to target: Improving the odds for successful drug developmentTher. Deliv.2016745748110.4155/tde-2016-001627403630Search in Google Scholar
Rakoff-Nahoum S.: Why cancer and inflammation? Yale J. Biol. Med., 2006; 79: 123–130Rakoff-NahoumS.Why cancer and inflammation?Yale J. Biol. Med.200679123130Search in Google Scholar
Ruggeri R.M., Campennì A., Giuffrida G., Trimboli P., Giovanella L., Trimarchi F., Cannavò S.: Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know). J. Endocrinol. Invest., 2019; 42: 745–756RuggeriR.M.CampennìA.GiuffridaG.TrimboliP.GiovanellaL.TrimarchiF.CannavòS.Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know)J. Endocrinol. Invest.20194274575610.1007/s40618-018-0984-z30471004Search in Google Scholar
Scott E.S., Long G.V., Guminski A., Clifton-Bligh R.J., Menzies A.M., Tsang V.H.: The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur. J. Endocrinol., 2018; 178: 173–180ScottE.S.LongG.V.GuminskiA.Clifton-BlighR.J.MenziesA.M.TsangV.H.The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanomaEur. J. Endocrinol.201817817318010.1530/EJE-17-081029187509Search in Google Scholar
Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Finley G., Kelsch C., Lee A., Coleman S., Deng Y., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med., 2018; 378: 2288–2301SocinskiM.A.JotteR.M.CappuzzoF.OrlandiF.StroyakovskiyD.NogamiN.Rodríguez-AbreuD.Moro-SibilotD.ThomasC.A.BarlesiF.FinleyG.KelschC.LeeA.ColemanS.DengY.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLCN. Engl. J. Med.20183782288230110.1056/NEJMoa171694829863955Search in Google Scholar
Song M., Giovannucci E.: Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol., 2016; 2: 1154–1161SongM.GiovannucciE.Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United StatesJAMA Oncol.201621154116110.1001/jamaoncol.2016.0843501619927196525Search in Google Scholar
Suzuki M., Kato C., Kato A.: Therapeutic antibodies: Their mechanisms of action and the pathological findings they induce in toxicity studies. J. Toxicol. Pathol., 2015; 28: 133–139SuzukiM.KatoC.KatoA.Therapeutic antibodies: Their mechanisms of action and the pathological findings they induce in toxicity studiesJ. Toxicol. Pathol.20152813313910.1293/tox.2015-0031458820726441475Search in Google Scholar
Tecentriq – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/tecentriq-epar-product-information_en.pdf (25.09.2020)Tecentriq – Summary of Product Characteristicshttps://www.ema.europa.eu/en//documents/product-information/tecentriq-epar-product-information_en.pdf (25.09.2020)Search in Google Scholar
Tolcher A.W.: Antibody drug conjugates: Lessons from 20 years of clinical experience. Ann. Oncol., 2016; 27: 2168–2172TolcherA.W.Antibody drug conjugates: Lessons from 20 years of clinical experienceAnn. Oncol.2016272168217210.1093/annonc/mdw42427733376Search in Google Scholar
Toporcov T.N., Wünsch Filho V.: Epidemiological science and cancer control. Clinics, 2018; 73: e627sToporcovT.N.Wünsch FilhoV.Epidemiological science and cancer controlClinics201873e627s10.6061/clinics/2018/e627s614285830281702Search in Google Scholar
Torino F., Corsello S.M., Salvatori R.: Endocrinological side-effects of immune checkpoint inhibitors. Curr. Opin. Oncol., 2016; 28: 278–287TorinoF.CorselloS.M.SalvatoriR.Endocrinological side-effects of immune checkpoint inhibitorsCurr. Opin. Oncol.20162827828710.1097/CCO.000000000000029327136136Search in Google Scholar
U.S. Cancer Statistics Working Group. 1999–2013 Incidence and mortality web-based report. www.cdc.gov/uscs (25.09.2020)U.S. Cancer Statistics Working Group1999–2013 Incidence and mortality web-based reportwww.cdc.gov/uscs (25.09.2020)Search in Google Scholar
Venetsanaki V., Boutis A., Chrisoulidou A., Papakotoulas P.: Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr. Oncol., 2019; 26: e111–e114VenetsanakiV.BoutisA.ChrisoulidouA.PapakotoulasP.Diabetes mellitus secondary to treatment with immune checkpoint inhibitorsCurr. Oncol.201926e111e11410.3747/co.26.4151638064030853817Search in Google Scholar
Weber J.S., Postow M., Lao C.D., Schadendorf D.: Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist, 2016; 21: 1230–1240WeberJ.S.PostowM.LaoC.D.SchadendorfD.Management of adverse events following treatment with anti-programmed death-1 agentsOncologist2016211230124010.1634/theoncologist.2016-0055506153927401894Search in Google Scholar
Weiner L.M., Surana R., Wang S.: Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol., 2010; 10: 317–327WeinerL.M.SuranaR.WangS.Monoclonal antibodies: Versatile platforms for cancer immunotherapyNat. Rev. Immunol.20101031732710.1038/nri2744350806420414205Search in Google Scholar
Win M.A., Thein K.Z., Qdaisat A., Yeung S.C.: Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am. J. Emerg. Med., 2017; 35: 1039.e5–1039.e7WinM.A.TheinK.Z.QdaisatA.YeungS.C.Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidismAm. J. Emerg. Med.2017351039.e51039.e710.1016/j.ajem.2017.02.04828363614Search in Google Scholar
World Health Organization. Cancer fact sheet. http://www.who.int/mediacentre//factsheets/fs297/en/ (25.09.2020)World Health OrganizationCancer fact sheethttp://www.who.int/mediacentre//factsheets/fs297/en/ (25.09.2020)Search in Google Scholar
Yamazaki N., Kiyohara Y., Uhara H., Fukushima S., Uchi H., Shibagaki N., Tsutsumida A., Yoshikawa S., Okuyama R., Ito Y., Tokudome T.: Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol., 2015; 76: 997–1004YamazakiN.KiyoharaY.UharaH.FukushimaS.UchiH.ShibagakiN.TsutsumidaA.YoshikawaS.OkuyamaR.ItoY.TokudomeT.Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanomaCancer Chemother. Pharmacol.201576997100410.1007/s00280-015-2873-x461232126410424Search in Google Scholar
Yervoy-Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf (25.09.2020)Yervoy-Summary of Product Characteristicshttps://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf (25.09.2020)Search in Google Scholar
Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103: 365–369ZhaoC.TellaS.H.Del RiveroJ.KommalapatiA.EbenuwaI.GulleyJ.StraussJ.BrownellI.Anti-PD-L1 treatment induced central diabetes insipidusJ. Clin. Endocrinol. Metab.201810336536910.1210/jc.2017-01905580082629220526Search in Google Scholar